SCHEMBL15034159

SCHEMBL15034159

CC1(C)CN(C(=O)c2ccnc(C(F)(F)F)n2)CCN1C(=O)c1ncn(-c2ccccc2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.39
TP53 P04637 5/20 0.34
SMN1; SMN2 Q16637 4/20 0.34
MAPT P10636 8/20 0.34
ALDH1A1 P00352 2/20 0.33
USP2 O75604 1/20 0.33
TSHR P16473 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
PKM P14618 1/20 0.33
ACKR3 P25106 3/20 0.33
MGLL Q99685 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
POLB P06746 1/20 0.32
HPGD P15428 1/20 0.32
ALOX15 P16050 1/20 0.32
HSD17B10 Q99714 1/20 0.32
F2RL1 P55085 1/20 0.32
JAK2 O60674 1/20 0.32
JAK1 P23458 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15034121 0.87 IRAK4 (0.37) CFTRTP53SMN1; SMN2MAPTALDH1A1
SCHEMBL15034165 0.85 PKM (0.41) CFTRTP53SMN1; SMN2MAPTALDH1A1
SCHEMBL15034178 0.83 USP19 (0.40) CFTRTP53SMN1; SMN2MAPTALDH1A1
SCHEMBL15034145 0.83 MAPT (0.40) CFTRTP53SMN1; SMN2MAPTALDH1A1
SCHEMBL15034134 0.81 CFTR (0.44) CFTRTP53SMN1; SMN2MAPTALDH1A1
SCHEMBL15034128 0.80 CFTR (0.42) CFTRTP53SMN1; SMN2MAPTMGLL
SCHEMBL15034351 0.80 CFTR (0.37) CFTRTP53SMN1; SMN2MAPTALDH1A1
SCHEMBL15023304 0.80 CFTR (0.39) CFTRTP53SMN1; SMN2MAPTALDH1A1
SCHEMBL15034129 0.80 CFTR (0.39) CFTRTP53SMN1; SMN2MAPTALDH1A1
SCHEMBL15034224 0.80 CFTR (0.36) CFTRTP53SMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158042-A1 NOVEL COMPOUNDS GRM5, GRIK5, GRM1 CFTR 3753/4885TP53 3722/4885SMN1; SMN2 2592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.